We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Ret5.5
Retatrutide Research
Mostly mechanism / observational
28 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Retatrutide studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2022–2026 with a typical study size of 15,584 participants.
Based on 28 studies · 8 meta-analyses · 8 RCTs · 169,791 total participants
Confidence
High confidence
By outcome
Weight managementIn the 48-week phase-2 obesity trial the 12 mg dose produced ~24.2% mean weight loss; phase-3 confirmation still pending · Progressive over 24-48 weeks
Mostly mechanism / observational20 studies
Glucose & glycemic controlDose-dependent HbA1c reductions in type 2 diabetes (top doses ~-2.0%, outperforming dulaglutide) · By 24-36 weeks · Combined large weight loss, liver-fat reduction and glycemic control point to broad metabolic benefit (phase-2) · By 24-48 weeks
Mostly mechanism / observational15 studies
Safety profile
Mostly mechanism / observational7 studies
Liver fat & MASLDIn a phase-2a MASLD substudy, liver fat fell ~81-82% at 8/12 mg; promising but early, no histology/outcome data · By 24 weeks
Too few graded studies2 studies
Active research area
28 studies in the last 5 years · Latest meta-analysis: 2026
20222026
1Meta-Analysis2025
Yin Y, Zhang M, Cao Q, Lin L, Lu J, Bi Y · J Diabetes (2025)
In plain English: However, this difference is likely minimal, given the numerous studies excluded from the meta-analysis where both treatment arms had zero events.
Wen J, Nadora D, Bernstein E, How-Volkman C, Truong A, Joy B, Kou M, Muttalib Z, Alam A, Frezza E. · Endocrinology, diabetes & metabolism (2025)
Meta-analysis showed a significantly increased risk of pancreatitis (RR: 1.44, 95% CI 1.09-1.89, p = 0.009), but not when stratified by background medications (RR: 1.28, 95% CI 0.87-1.87) and without background medications (RR: 1.37, 95% CI 0.91-2.05).
Pancreatic cancer and GLP-1 RA use showed no significant association (RR: 1.30, 95% CI 0.86-1.97).
However, a significant increase was found with background medications (RR: 1.85, 95% CI 1.05-3.26, p = 0.03), but not without (RR: 0.81, 95% CI 0.43-1.55).
In plain English: Funding The study was funded by Eli Lilly and Company.
Coskun T, Wu Q, Schloot NC, Haupt A, Milicevic Z, Khouli C, Harris C. · The lancet. Diabetes & endocrinology (2025)
This substudy assessed percent change from baseline to week 36 in total body fat mass versus placebo and dulaglutide.
Eligible participants were adults aged 18-75 years with type 2 diabetes, HbA 1c of 7·0-10·5%, stable bodyweight, and BMI of 25-50 kg/m 2 .
The prespecified primary substudy endpoint was percent change from baseline to week 36 in total fat mass, as measured by dual-energy X-ray absorptiometry (DXA).
In plain English: GLP-1RAs also significantly improved glycemic control for patients with T2D, with tirzepatide performing the best for glycemic control.
Zhang S, Yu B, Xu J, Jin S, Li Y, Bing H, Li J, Ma X, Zhang X, Zhao L. · Diabetes technology & therapeutics (2025)
In terms of Δ body weight, retatrutide (12 mg qw) was the most effective treatment (mean difference = -26.56% [95% confidence interval: -43.89% to -3.01%]).
Tirzepatide (15 mg qw) demonstrated good weight loss ability in all three ΔBW models, ΔBW-NDOOG (-22.76% [-26.45% to -18.50%]), ΔBW-T2DCG (-11.09% [-12.39% to -9.44%])), and ΔBW-T2DAG (-4.97% [-5.84% to -4.12%]).
GLP-1RAs also significantly improved glycemic control for patients with T2D, with tirzepatide performing the best for glycemic control.
In plain English: Incretin-based therapy led to a modest but clinically meaningful BP reduction and lower all-cause mortality in adults with overweight or obesity, without excess in hypoglycaemia or pancreatitis episodes.
Basile C et al. · European journal of preventive cardiology (2026)
Random effects meta-analyses generated mean differences (MDs) or risk ratios (RRs) along with 95% confidence intervals (CIs).
GLP1-RAs reduced SBP by 3.4 mmHg (95% CI 2.8-4.0) and DBP by 0.9 mmHg (95% CI 0.5-1.2).
All-cause mortality was reduced by 18% (RR 0.82, 95% CI 0.76-0.90).
In plain English: This perspective underscores the urgent need for scientific engagement, equity considerations, and policy preparedness, positioning retatrutide as a watershed in obesity treatment and a blueprint for future poly-agonist therapies.
Ganamurali N, Sabarathinam S. · Clinical pharmacology in drug development (2026)
Retatrutide (LY3437943), a novel triple agonist targeting GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors, represents a transformative advance in obesity pharmacotherapy.
Phase 2 trials report unprecedented weight reductions, comparable to bariatric surgery, with additional benefits for metabolic comorbidities such as NASH and cardiovascular disease.
Retatrutide exemplifies rational multi-agonist peptide engineering and signals a paradigm shift in systems pharmacology.
In plain English: This review provides an updated synthesis of therapeutic developments and outlines priorities for future research, regulatory policy, and equitable global integration as incretin-based therapies have evolved into a versatile class addressing glycaemic control, weight loss, and cardio-metabolic risk.
Gupta M et al. · The Indian journal of medical research (2026)
Dual GIP/GLP-1 agonist tirzepatide and triple agonist retatrutide have shown unprecedented efficacy, with up to 24% body weight reduction and improvement in hepatic and inflammatory markers.
Despite promising outcomes, challenges persist in terms of cost, accessibility, and the underrepresentation of low- and middle-income countries in major trials.
Pharmacogenomic variability may also influence therapeutic response.
In plain English: Its potential for kidney protection is promising, though clinicians should be mindful of managing gastrointestinal tolerability.
Pallavi K, Chandra A, Kumar K, Martand K, Sahu SS, Mohan L, Verma A. · Maedica (2025)
A significant mean reduction in HbA1c of -1.04% (95% CI -1.42 to -0.67) and a noticeable loss in weight, reaching up to -24.2%, were both linked with retatrutide treatment.
A subgroup analysis indicated that the glycemic benefits were dose-dependent, with lower doses (≤8 mg) demonstrating a greater HbA1c reduction (-1.39%) than higher doses (≥12 mg, -0.65%).
Furthermore, secondary analyses pointed toward possible renoprotective effects, evidenced by a reduction in albuminuria.
In plain English: Our results suggest that enhanced modification of eating behaviours with retatrutide may assist with weight reduction in adults with type 2 diabetes.
Kanu C, Boye KS, Poon JL, Goetz I, Williamson S, Lou J, Hartman ML, Martin CK, Coskun T. · Diabetes, obesity & metabolism (2025)
Results Compared with placebo, participants who received retatrutide ≥4 mg reported greater reductions from baseline in overall appetite, hunger, and prospective food consumption (l at Week 24 (all p <0.05)).
Dietary Restraint increased from baseline versus placebo only in participants who received retatrutide 12 mg at Week 36 (all p <0.05).
WHAT WERE THE MAIN RESULTS?: This study showed that adults with type 2 diabetes who received higher doses of retatrutide reported being less likely to feel hungry or overeat compared to those who received no treatment (i.e., placebo) or those who received dulaglutide.
In plain English: Dual or triple receptor agonists (GLP-1 plus glucose-dependent insulinotropic polypeptide and/or Glucagon receptor) are more effective for weight loss than GLP-1 receptor agonists.
Xie Z, Zheng G, Liang Z, Li M, Deng W, Cao W. · Metabolism: clinical and experimental (2024)
The primary outcome was the percentage change in body weight from baseline.
In addition, disparities in race, BMI, and treatment cycles did not significantly increase the incidence of adverse events.
Finally, the sensitivity and publication bias analyses indicated that the basic analysis results were reliable.
In plain English: Summary Retatrutide, a triple agonist now in phase 3 trials, has the potential to become the most effective pharmacological treatment for obesity while also offering substantial benefits in T2D management and other cardiometabolic risk factors.
Goldney J, Hamza M, Surti F, Davies MJ, Papamargaritis D. · Current cardiovascular risk reports (2025)
Retatrutide achieved up to 24.2% mean weight loss after 48 weeks in individuals with obesity and 16.9% in those with T2D after 36 weeks.
In the T2D study, HbA1c improved by 2.2%, with 82% of participants reaching HbA1c ≤ 6.5%.
Retatrutide also improved multiple cardiometabolic parameters, including blood pressure, lipids, waist circumference, and liver fat (82% reduction in hepatic steatosis).